UBS upgraded Jazz Pharmaceuticals (JAZZ) to Buy from Neutral with a price target of $179, up from $145. The company’s base business strength ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback